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osting by EAbstract Aim: The current study aimed to prepare a sustained release tablet for a drug which has
poor solubility in alkaline medium using complexation with cyclodextrin. Nicardipine hydrochlo-
ride (NC) a weak basic drug was chosen as a model drug for this study.
Method: Firstly the most suitable binary system NC-HPbCD was selected in order to improve drug
solubility in the intestinal media and then embedding the complexed drug into a plastic matrix, by
fusion method, consists of glycerol monostearate (GMS) as an inert waxy substance and polyeth-
ylene glycol 4000 (PEG4000) as a channeling agent, after that the ﬁnal solid dispersion
[(NC:HPbCD):GMS:PEG4000] which was prepared at different ratios was mixed with other excip-
ients, avicel PH101, lactose, and talc, to get a tablet owning dissolution proﬁle complying with the
FDA and USP requirements for the extended release solid dosage forms.
Results: Infrared spectroscopy (IR), differential scanning colorimetry (DSC), polarized microscopy
and X-ray diffractometry proved that the coevaporation technique was effective in preparing amor-
phous cyclodextrin complexes with NC and trapping of NC within the HPbCD cavity by dissolving
both in ethanol and evaporate the solvent using a rotavapor at 65 C. Dissolution proﬁle of NCyali Chair for Pharmaceutical
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246 H. Al-Zein et al.enhanced signiﬁcantly in pH 6.8 from NC:HPbCD inclusion complex prepared by the rotavapor
(t-test Student p< 0.05). The release of NC from tablet containing [(NC:HPbCD):GMS:PEG4000]
[(1):0.75:0.5] (w/w/w) solid dispersion (F8) was complying with the FDA dissolution requirements
for extended release dosage forms, and studying the kinetics of the release showed that the diffu-
sional contribution is the major factor controlling the drug release from that formula.
Conclusion: The prepared waxy matrix tablet containing NC complexes with CD shows promising
results as extended release tablets.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
To get a successful sustained release product, the drug must be
released from the dosage form at a predetermined rate and dis-
solve in the gastrointestinal ﬂuids. Nicardipine hydrochloride
(NC), a calcium channel-blocking, is a weak basic drug
pKa = 7.2 and widely used to treat mild to moderate hyper-
tension (Abernethy and Schwartz, 1988; Graham et al.,
1985). The drug in its conventional formulation undergoes
extensive ﬁrst pass effect which often results in a very limited
bioavailability (15–40%) Higuchi et al., 1980; Sorkin and
Clissold, 1987, highly soluble in acidic pH while sparingly
soluble in neutral and alkaline pH which means the in vivo
efﬁcacy of its sustained release formulations may be limited
by the variability in the drug solubility and the dissolution rate
at different pH values of the gastrointestinal tract.
The USP and FDA (Welling and Tse, 1988), identify spe-
ciﬁc dissolution requirements for extended release dosage
forms which involve sampling three times, expressed as frac-
tions of the normal dosing interval (D). Releasing of 20–
50% of the drug after 0.25 D assures that there is no dose
dumping from the dosage form. The intermediate speciﬁcation
assures that drug release (45–75%) over the 0.25–0.5 D period
occurs neither too slowly nor too rapidly, while the purpose of
the last speciﬁcation is to assure complete dissolution of the
drug. From a practical stand point, sampling through 8 h for
a twice daily product and through 12 h for a once daily prod-
uct may be adequate, provided that not less than 75–80% of
drug has been released (Welling and Tse, 1988).
Many trials have been made to prepare sustained release
tablets of NC. Hybridization of NC/hydrophilic b cyclodex-
trins complexes was used as a fast releasing fraction, and
NC/hydrophobic b cyclodextrins complex, as a slow release
fraction in different mixing ratios to offer a suitable modiﬁed
release formulation of NC, with prolonged therapeutic effect
(Fernandes and Veiga, 2002). In other studies NC-alginate
gel beads were prepared to extend the release of NC in differ-
ent dissolution media (Takka et al., 1998), formulating NC in
sustained release ﬂoating capsules using hydrocolloid of high
viscosity grade (Moursy et al., 2003), and using HPMC in con-
trolling the release of NC from the tablet containing PEG4000
(El-Zein, 2008). More studies are needed to further develop
and investigate more technologies to attain sufﬁciently ade-
quate sustain-releasing dissolution of NC.
Therefore, to sustain the dissolution rate of NC along the
gastrointestinal tract, the current study was designed to in-
crease the solubility and dissolution rate of NC in intestinal
media by complexation with hydrophilic cyclodextrin deriva-
tive HPbCD which is considered as a solubilizing excipient in
oral formulation (Robert, 2004) and then controlling therelease by embedding the complexed drug in the plastic ma-
trix that consists of the glycerol monostearate as an inert
waxy substance and PEG4000 as a channeling agent. The in-
ert plastic matrix was mixed with avicel PH101, lactose and
talc. Afterward it was compressed into tablets by direct com-
pression. The prepared NC tablets were evaluated via disso-
lution in simulated gastric ﬂuid pH 1.2 and Sorenson’s
buffer pH 6.8.
2. Materials and methods
Nicardipine hydrochloride (NC) was purchased from IRCA
(Albania). Hydroxy propyl b cyclodextrin HPbCD (Degree
of substitution 4.2) was purchased from NIHON Shokuhin
Kako Co. Ltd. (Japan). Glycerol monostearate GMS and talc
were purchased from Merck (Germany). Polyethylene glycol
PEG4000 was purchased from Interpharm Ltd. (UK). Avicel
PH101 was purchased from FMC Corporation, (Philadelphia,
USA). Methanol and Ethanol were purchased from Romil
Chemical Limited (England). Lactose was purchased from
Scharlau chemie (Spain).
2.1. Preparation of nicardipine binary systems
2.1.1. Kneading method
Nicardipine (NC) and hydroxy propyl b cyclodextrin HPbCD
in a 1:1 M ratio which is equivalent to 236 and 1450 mg were
mixed and moistened and then kneaded in a mortar by a mix-
ture of water:ethyl alcohol at ratio 1:1 v/v for 45 min. The mix-
ture was evaporated in an oven at 40 C for 48 h and afterward
the rest were collected and milled in a mortar. The particles be-
tween 100 and 160 lm where used later.
2.1.2. Evaporation method
Complex of NC:HPbCD was prepared in a 1:1 M ratio
(Catarina et al., 2002) by the solvent method using ethyl alco-
hol (El-Zein et al., 1998). NC and HPbCD equivalent to 236
and 1450 mg, respectively, were dissolved separately in ethanol
and then mixed for 1 h. The mixture was evaporated using a
rotavapor (BUCHI R-200, Switzerland) at 65 C, rotation
speed 100 rpm. The resultant ﬁlm was removed and stored
over silica in a desiccator at room temperature. Afterward
the rest were collected and milled. The particles between 160
and 100 lm, were used later.
2.2. Preparation of solid dispersion
Solid dispersions of (NC:GMS) and (NC:HPbCD):GMS were
prepared by the fusion method. The accurately weighed
Table 1 The composition of the nicardipine systems.
Nicardipine System Nicardipine (mg) PEG (mg) GMS (mg) HPbCD (mg)
(Solid dispersion) NC:GMS (SD1) (1:7)(w/w) 20 – 143 –
(Solid dispersion) NC:GMS:PEG4000 (SD2) (1:7:3.5) (w/w/w) 20 72 143 –
(Solid dispersion) NC:GMS:PEG4000 (SD3) (1:5.5:3.5) (w/w/w) 20 72 108 –
(Kneaded complex) NC:HPbCD (SY1) (1 M:1 M) 20 – – 123
(Evaporated complex) NC:HPbCD (SY2) (1 M:1 M) 20 – – 123
SY2:GMS (SY3) (1:1)(w/w) 20 – 143 123
SY2:GMS:PEG4000 (SY4) (1:1:0.5) (w/w/w) 20 72 143 123
SY2:GMS:PEG4000 (SY5) (1:0.75:0.5) (w/w/w) 20 72 108 123
Table 2 The formulation of nicardipine tablets.
Formula (mg) F1 F2 F3 F4 F5 F6 F7 F8
Nicardipine powder 20 – – – – – – –
Lactose 345 202 130 165 222 79 7 42
SD1 – 163 – – – – – –
SD2 – – 235 – – – – –
SD3 – – – 200 – – – –
SY2 – – – – 143 – – –
SY3 – – – – – 286 – –
SY4 – – – – – – 358 –
SY5 – – – – – – – 323
Avicel PH101 80 80 80 80 80 80 80 80
Talc 5 5 5 5 5 5 5 5
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placed in a porcelain dish and melted over a thermostati-
cally-controlled water path at 75 C. When a homogenous melt
was obtained, the accurately weighed amount of NC or
NC:HPbCD, which was prepared from the last step, was
added in small portions and the mixture was stirred after each
addition. When all the NC or NC:HPbCD was incorporated,
the molten mass was quickly solidiﬁed by cooling and contin-
uous stirring over ice. The weights of NC and NC:HPbCD and
waxes were calculated so as to produce the desired ratios
shown in Table 1. The resulting solid dispersion was stored
in desiccators over silica for at least 48 h, prior to use. The so-
lid dispersion was ground in a porcelain mortar. Particles
which passed through, sieve size 314 lm and were retained
on sieve size 100 lm (CISA SIEVE SHAKER, MOD.RP.09,
SPAIN) were used in the dissolution studies. The compositions
of the prepared nicardipine systems are presented in Table 1.
2.3. Infrared spectroscopy
The spectra of pure nicardipine, hydroxy propyl b cyclodextrin
HPbCD, glycerol monostearate GMS and their mixtures were
collected on IR spectroscopy (IR spectroscopy Bruker Vecctor
22, Germany) at 4 cm1 resolution for scans. Samples (about
1% w/w) were mixed with KBr powder and compressed to a
12 mm disc by a hydraulic press at 10 tons compression force
for 30 s. The disc was placed in the sample holder and scanned
from 400 to 4000 cm1.
2.4. Differential scanning calorimetry
Differential scanning calorimetry (DSC) thermograms of the
samples (3–6 mg) were recorded using a thermal analysis sys-tem (SETARAM.DSC 131, France). After calibration with in-
dium and lead standards, the samples were heated at 10 C/
min in an aluminum pan under nitrogen atmosphere. A similar
empty pan was used as the reference. The samples were
scanned from 25 to 300 C.2.5. X-ray powder diffraction
Data were collected on powdered samples using diffractometer
(STOE, Germany).The instrument used monochromated
CuKa radiation at k= 1.5406 A˚. Samples were analyzed
through a 2h range of 5–30 and scan speed 0.05 step.2.6. Polarized microscopy
The surface morphologies of the raw substances NC, and
HPbCD and the binary systems NC:HPbCD prepared by
kneading and evaporation methods were examined by a polar
microscope (CARL ZEISS 1100, Germany). The powder of
each was mixed with 2 drops of parafﬁn oil on glass plate
and examined by 40/0.65 lens.
2.7. Preparation of nicardipine tablet
NC tablets were prepared by mixing NC powder or systems
with avicel PH101 and lactose in a mortar for 10 min. After-
ward, talc was added and mixed for 2 min. The mixture was
compressed into tablets by direct compression using a single-
punch tableting machine (Erweka AR 402, Germany) with a
ﬂat-faced punch (8 mm diameter). It should be noted that
the hardness were 50–80 N. The formulations of tablets are
presented in Table 2.
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2.8.1. Drug content
Prior to any in vitro evaluation, NC systems were freshly pre-
pared and NC content was determined in duplicate for each
system. An amount equivalent to 10 mg NC was accurately
weighed and placed in a 10 ml volumetric ﬂask to prepare a
1 mg/ml solution in methanol. Fifty microliters of NC solution
(1 mg/ml) was added to 5 ml distilled water to yield a theoret-
ical concentration of 10 mg/ml. The sample was measured at
kmax 244 nm by a UV spectrophotometer (HACH DR/4000,
USA) and NC concentration was calculated from the standard
curve prepared simultaneously.
2.8.2. Dissolution studies
For each system as well as plain NC, dissolution was run in
triplicate. An accurately weighed amount of the prepared inclu-
sion complex contained 20 mg NC that was placed in each ves-
sel in a modiﬁed USP dissolution basket covered with the
stainless steel screen (mesh size 100 lm) (Pharmatest PT-
DT7, Germany). Dissolution was carried out in 900 ml dissolu-
tion medium (0.1 N HCl pH 1.2, Sorenson buffer pH 6.8). The
basket was rotated at 100 ± 5 rev/min, and the dissolution
medium maintained at 37 C. One-milliliter aliquot samples
were withdrawn with replacement at 5, 10, 15, 30, 45, 60, 90,
and 120 min. Samples were ﬁltered by using 0.45 lm, mill-
pore and properly diluted prior to measuring their absor-
bance at 244 nm (Takka et al., 1998). The corresponding
concentrations were determined from the linear regression
equation of the standard curve run simultaneously. On the
other hand, dissolution test for the prepared tablets was carried
out using USP dissolution apparatus II. The dissolution med-
ium was 900 ml 0.1 N HCl for 2 h and then changed to Soren-
son buffer pH 6.8 for addition 6 h. Other dissolution conditions
(temperature and rotation speed) were kept the same as for the
plain NC and the inclusion complex.
2.9. Drug release kinetic
Data from the in vitro drug release were analyzed by different
equations and kinetic models in order to evaluate the release
mechanism of NC from the matrices. The kinetic models used
were:
(a) Korsmeyer and Peppas model (1981)nMt=M1 ¼ KPt ; ð1Þ
where Mt/M1 is the fraction of the drug release at time t
(ﬁrst 60%), kp is a constant incorporating the properties
of the macromolecular polymeric system and the drug. n
is an exponent used to characterize the transport
mechanism. For example, n= 0.45 for Case I or Fickian
diffusion, 0.45 < n < 0.89 for anomalous behavior or
non-Fickian transport, n = 0.89 for Case II transport,
and n > 0.89 for Super Case II transport (Korsmeyer
and Peppas, 1981). Fickian diffusional release occurs by
the usual molecular diffusion of the drug due to a chem-
ical potential gradient. Case II relaxational release is the
drug transport mechanism associated with stresses and
state-transition in hydrophilic glassy polymers, which
swell in water or biological ﬂuids. This term also includespolymer disentanglement and erosion (Peppas and Sahlin,
1989).(b) Peppas and Sahlin equation (1989):Mt=M1 ¼ K1tm þ K2t2m; ð2Þ
where the ﬁrst term on the right side represents the contri-
bution of Fickian diffusion and the second term repre-
sents the contribution of Case II transport. The
coefﬁcient m is purely the exponent for Fickian diffusion
for any geometric form.
The drug percentage due to Fickian diffusion mechanism
(F) is clearly calculated as:F ¼ 1
1þ K2
K1
tm
ð3Þ2.10. Statistical analysis
All the data were statistically analyzed by two-tailed t-test
Student two tails by SPSS statistical software (SPSS Version
13). Results are quoted as signiﬁcant where p< 0.05.3. Results and discussion
3.1. Differential scanning calorimetry
Fig. 1 summarizes the DSC for all complexes examined versus
plain NC and the carrier HPbCD and GMS. The thermogram
of the evaporated complex NC:HPbCD shows disappearance
of the characteristics NC melting peak at 172.2 C, while that
peak is shifted in the kneaded complex to lower temperature
(163.8 C). This suggests that NC is totally entrapped inside
HPbCD in evaporated complex and formation of an amor-
phous solid dispersion (Pomponio et al., 2004). This result
indicates that the complex could be accompanied by more suit-
able dissolution proﬁle along the whole gastro-intestinal tract
and allows the use of it in the waxy matrix to get drug delivery
system with a sustained release of NC. On the another hand
the thermogram of NC:GMS solid dispersion shows the char-
acteristics NC melting peak at 172 C and small shifting of the
GMS characteristic peak from 67 to 61 C which may be an
evidence that NC has not undergone any change during prep-
aration of the solid dispersion between NC and GMS.
3.2. X-ray powder diffraction (XRPD)
Fig. 2 shows X-ray diffraction patterns of pure NC, HPbCD,
GMS, NC:HPbCD inclusion complexes prepared by rotava-
por and kneading method and NC:GMS solid dispersion. Pure
NC exhibited a series of characteristic peaks specially those in
the 2h angle located at 7, 14, and 22 which proved the crys-
talline nature of NC. Differently, no characteristic peak ap-
peared on the X-ray diffractometer of HPbCD revealing the
amorphous nature of this carrier. Similarly, the kneaded inclu-
sion complex shows diffraction pattern similar to that of single
components, while that obtained from the rotavapor shows a
diffraction pattern that completely diffuses. It could be sug-
gested that NC was totally entrapped within the complex.
Lack of crystallinity and the new amorphous nature of the
Figure 1 DCS curves of pure nicardipine (NC), hydroxypropyl b
cyclodextrin (HPbCD), glycerol monostearate (GMS), nicardipine
(NC):hydroxypropyl b cyclodextrin (HPbCD) kneaded complex,
nicardipine (NC):hydroxypropyl b cyclodextrin (HPbCD) evapo-
rated complex and nicardipine (NC):glycerol monostearate (GMS)
solid dispersion.
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that the dissolution proﬁle of NC in intestinal media is com-
pletely changed to the higher one. While in solid dispersion,
NC shows the same characteristic peaks which may prove that
the crystalline nature of NC has not affected by preparing it
with GMS as a solid dispersion.
3.3. Fourier transform infrared spectroscopy
Figs. 3 and 4 show IR spectrums of pure NC, HPbCD, and
NC:HPbCD inclusion complexes prepared by rotavapor andFigure 2 X-ray diffraction patterns of pure nicardipine (NC), hydro
nicardipine (NC):hydroxypropyl b cyclodextrin (HPbCD) kneaded co
evaporated complex and nicardipine (NC):glycerol monostearate (GMkneading method. FTIR spectroscopy was used to assess the
interaction between CD and guest molecules in the solid state.
Due to complexation, disappearances, shifts or changes in the
absorption spectrum may occur. The IR spectra of HPbCD
show prominent absorption bands at 3414 cm1 (for O–H
stretching vibrations), 2933 cm1 (for C–H stretching vibra-
tions), and 1164, 1083 cm1, (C–H, C–O stretching vibration).
The two characteristic bands of NC are located at 1704 cm1
(C‚O stretching) and at 1175 cm1 (C–O–C stretching) vibra-
tions of the IR spectra. They were used for diagnostic purposes
and for the analysis of solid interactions in both the kneaded
and evaporation systems. Nicardipine (C–O–C) stretching
vibration of evaporation complex shifts toward a higher wave-
length of 1190 cm1 conﬁrms the existence of interaction of the
drug and HPbCD. In addition, the nicardipine C‚O stretch-
ing band was highly diminished, in spectral patterns of
kneaded and evaporation systems. It was veriﬁed that the mag-
nitude of alteration of the original C‚O stretching band was
clearly affected by the preparation method selected. Thus, the
decrease in the intensity of C‚O stretching band was in the
following range kneaded < evaporated. Similar results have
been reported by other authors and attributed to the forma-
tion, during inclusion complexation, of hydrogen bonds be-
tween the carbonyl groups of NC and the hydroxyl groups
of the host cavity (Fernandes and Veiga, 2002; Pomponio
et al., 2004). In conclusion, solid state studies carried out by
DSC, X-ray diffraction and FT-IR pointed out that the coeva-
poration technique was effective in preparing amorphous
cyclodextrin complexes with NC, which might have an impor-
tant inﬂuence on increasing dissolution rate of NC in intestinal
media. While Fig. 4 shows IR spectra of pure NC, GSM, and
NC:GMS solid dispersion depending on the characteristic
peaks for NC and GMS, there were not any interactions.
3.4. Polarized microscopy
Fig. 5 shows photomicrograph of nicardipine, hydroxy propyl
b cyclodextrin HPbCD and their kneaded and evaporatedxypropyl b cyclodextrin (HPbCD), glycerol monostearate (GMS),
mplex, nicardipine (NC):hydroxypropyl b cyclodextrin (HPbCD)
S) solid dispersion.
Figure 3 FTIR spectra of pure nicardipine (NC), hydroxypropyl
b cyclodextrin (HPbCD) and their kneaded and evaporated
complex.
Figure 4 FTIR spectra of pure nicardipine (NC), glycerol
monostearate (GMS) and nicardipine (NC):glycerol monostearate
(GMS) solid dispersion.
Table 3 Drug release kinetics.
Korsmeyer–Peppas model
Formula n Kp r
2
F2 0.374 0.433 0.916
F3 0.378 0.525 0.923
F4 0.401 0.548 0.927
F6 0.346 0.344 0.950
F7 0.341 0.479 0.93
F8 0.761 0.681 0.998
250 H. Al-Zein et al.complex. NC appears as irregular-shaped crystals with golden
yellow polarization and some crystals are rectangular (extinc-
tion angle 20), while HPbCD presents as spherical particles
with no sign of optical properties. The kneaded complex ap-
peared as rectangular to shapeless ﬁne crystals which show a
golden yellow and blue birefringence (extinction angle 30),
while the evaporated complex presented as amorphous parti-
cles showing brown color in polarized alone and opaque color
in cross-Nichols (with no sign of optical properties). All
proved the amorphous nature of the evaporated complex.
The change to amorphous nature could be accompanied by
signiﬁcant change of dissolution behavior of NC in intestinal
medium.
3.5. Analysis of drug content in binary systems
Actual drug content in each nicardipine systemwas determined.
The results are reported in Table 3. As can be seen, SD1, SD2,
SD3, SY1, SY2, SY3, SY4, and SY5 system showed a good
agreement between theoretical and actual drug contents.
3.6. In vitro dissolution studies
Fig. 6 shows the dissolution proﬁles of plain NC in 0.1 N HCl,
pH 1.2, where (92.97 ± 1.23)% of NC were dissolved after
120 min, was signiﬁcantly higher than from that in Sorenson’s
buffer, pH 6.8, where (21.88 ± 1.72)% of NC were dissolved
after 120 min and this is because NC is a weak basic drug.
The dissolution of 1:1 M ratio NC:HPbCD inclusion complex
prepared by kneading method was examined in comparison
with that prepared by rotavapor in Sorenson buffer pH 6.8.
The proﬁles are given in Fig. 7. At all examined points, the
1:1 M ratio of NC:HPbCD complex prepared by rotavapor
showed signiﬁcantly higher percentages dissolved than thatprepared by kneading method, p> 0.05, using 2-tailed un-
paired Student t-test. The signiﬁcant enhancement in dissolu-
tion proﬁle of the evaporated NC:HPbCD complex in
Sorenson buffer pH 6.8 (intestinal medium) could be due to to-
tal entrapment of NC inside the HPbCD cavity and formation
of amorphous solid dispersion (Pomponio et al., 2004) which
proved by DSC, and the new amorphous solid state following
complexation as conﬁrmed by X-ray diffraction and micro-
scopic exam. This result is in full agreement with that of
Fernandes et al. (2002) although the preparation method of
the complex in rotavapor is totally different. It is suggested
that dissolving NC in ethanol was practically effective in trap-
ping the whole molecule of NC in HPbCD cavity and giving
the same result obtained by Fernandes et al. (2002) who kept
stirring the aqueous suspension of NC for 24 h to get clear
solution before adding to aqueous solution of HPbCD.
3.7. Release study of nicardipine from the tablets
Fig. 8 shows the dissolution proﬁles of NC from tablets con-
taining NC alone and NC:GMS solid dispersion and
NC:GMS:PEG4000 solid dispersion formulas in 0.1 N HCl
pH 1.2 for 2 h and in phosphate buffer pH 6.8 for 6 h. Formu-
lations of tablets are presented in TableS 1 and 2. The percent
of NC dissolved in F1 which contained NC alone was
88.33 ± 0.5 after 120 min in acidic medium(pH 1.2), the
Figure 5 Photomicrograph of’ nicardipine (A), hydroxypropyl b cyclodextrin (B), kneaded complex (C) and evaporated complex (D).
Table 4 Drug content in the nicardipine system.
Nicardipine system % Drug content
(±SD)
(Solid dispersion) NC:GMS(SD1) 100.63 ± 0.45
(Solid dispersion)NC:GMS:PEG4000 (SD2) 99.85 ± 0.63
(Solid dispersion) NC:GMS:PEG4000 (SD3) 100.35 ± 0.74
(Kneaded complex) NC:HPbCD (SY1) 99.64 ± 0.31
(Evaporated complex) NC:HPbCD (SY2) 100.15 ± 0.42
SY2:GMS (SY3) 99.76 ± 0.25
SY2:GMS:PEG4000 (SY4) 99.81 ± 0.21
SY2:GMS:PEG4000 (SY5) 100.02 ± 0.29
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Figure 6 Percent dissolved of nicardipine powder in 0.1 N HCl
pH 1.2 and phosphate buffer pH 6.8.
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Figure 7 Percent of pure nicardipine powder (NC) dissolved,
NC:HPbCD kneaded complex, and NC:HPbCD evaporated
complex phosphate buffer pH 6.8.
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dispersion of NC was 20.69 ± 1.37 after 480 min, in F3
PEG4000 were incorporated in solid dispersion system forimproving the percent release of NC by creating a channel in-
side the structure of the tablet and as a result of this the per-
cent dissolved of NC was elevated to be 33.95 ± 1.06 after
480 min, additional changes were done for rising the percent
of NC released from the tablet by decreasing the percent of
GMS in F4 where 43.72 ± 1.38 of NC were dissolved after
480 min, in F2–F4 the percent of the dissolved drug did not
undergo a signiﬁcant change after 120 min that is because
the medium of the dissolution was changed to alkaline where
NC is sparingly soluble in alkaline pH, while Fig. 9 shows
the dissolution proﬁles of NC from tablets containing NC
alone and from the waxy matrices (GMS:PEG4000) in addi-
tion to the evaporated complex (NC:HPbCD) formulas in
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Figure 8 Percent of nicardipine dissolved from (F1–F4) tablets
formulas in 0.1 N HCl pH 1.2 for 2 h, and in phosphate buffer pH
6.8 for 6 h.
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Figure 9 Percent of nicardipine dissolved from (F1) and (F5–F8)
tablets formulas in 0.1 N HCl pH 1.2 for 2 h, and in phosphate
buffer pH 6.8 for 6 h.
252 H. Al-Zein et al.0.1 N HCl pH 1.2 for 2 h and in phosphate buffer pH 6.8 for
6 h. Formulations of tablets are presented in Tables 1 and 2.
The percent of NC dissolved from F1 undergo incremental in-
creases with time, where the percent of NC dissolved after
120 min in acidic medium (pH 1.2) was 88.33 ± 0.5, while
F5 which contained evaporated complex released 88.23 ± 1.6
of NC after 10 min in acidic medium (pH 1.2) which is a strong
evidence on the effect of coevaporation technique on increas-
ing the dissolution rate of NC even in the acidic medium
(pH 1.2) which may be due to an entrapment of NC inside
the HPbCD cavity and formation of amorphous solid disper-
sion (Pomponio et al., 2004). On other hand, the mean
(±SD) of NC dissolved from F6 was 18.7 ± 1.8 after
120 min in acidic medium (pH 1.2), while it was 24.66 ± 2.3
at 240 min and 25.69 ± 1.71 at 480 min in phosphate buffer
(pH 6.8). The mean (±SD) percent of NC dissolved from F7
was 43.12 ± 2.47 after 120 min in acidic medium (pH 1.2),
and it was 47.1 ± 2.91 and 49.19 ± 2.02 at 240 and 480 min,
respectively, in phosphate buffer (pH 6.8). At all points during
the 8-h period, the F7 showed signiﬁcantly higher dissolution
percentage of NC dissolved than that of F6, using 2-tailedunpaired Student t-test, p< 0.05. It is suggested that the pres-
ence of PEG4000 as a channeling agent enhanced the release of
NC, but the proﬁle produced was still not in agreement with
USP and FDA dissolution requirements for extended release
dosage forms because it is less than 75% of NC released after
8 h. The dissolution proﬁle of F8 is in agreement with the dis-
solution requirements speciﬁed by the FDA and the USP. The
corresponding percent dissolved at 0.25 D (120 min), 0.5 D
(240 min) and D (480 min) were 43.58 ± 1.91, 72.91 ± 0.6,
and 88.01 ± 0.62, respectively. It could be concluded that
glycerol monostearate GMS with PEG4000 provide a blend
which is pH independent and could extend the release of NC
in the presence of HPbCD.
3.8. The kinetic of the release of nicardipine from the tablets
Using Korsmeyer and Peppas model, (1981) Eq. (1), n values
for F2–F4 and F6–F7 were less than 0.45 which indicate that
the release comply Case I or Fickian diffusion, which may
be due to the leaching of drug by the eluting medium (Table 4).
Fluid enters through the cracks and pores of the matrix with
diffusion of drug through the matrix being insigniﬁcant
(Dakkuri et al., 1978; Dredan et al., 1998). The higher rate
and extent of NC released in the ﬁrst two hours (within acidic
medium) was due to greater extraction of NC from the vicinity
of the matrix surface. NC, being highly soluble in acidic pH,
immediately released when it came into contact of the dissolu-
tion media. GMS based matrices show negligible swelling
property and hydrophobicity of these matrices is not sufﬁcient
enough to control this rapid release. The presence of lactose
and avicel in these formulations can also be considered as a
major factor for this rapid release. This imparted a disintegrat-
ing effect on the matrix as soon as it is immersed into the dis-
solution medium generating numerous pores depending on the
solubility of lactose and swelling effect of avicel (Akbari et al.,
2004; Ferrari et al., 1996; Algin et al., 2006; Sujja-areevath
et al., 1996). Through these pores ﬂuid diffused into and
stressed the integrity of the matrix-surface.
After liberation of the surface drug, the release of NC be-
came extremely slow and steady as the hydrophobic polymers
started impeding wetting and subsequent penetration of disso-
lution medium into the matrix. It is clear that there was a raise
in n value in F2–F4 and in F6–F8 which is an indicator that the
tablet tends to changing the mechanism of transportation of
drug from Case I or Fickian diffusion to anomalous behavior
or non-Fickian transport, The n value for F8 is 0.76 and this va-
lue is characteristic of anomalous kinetics (non-Fickian). This
suggests that some level of swelling and dissolution of matrix
must be operating within the system causing deviation from
the Fickian release. PEG4000 is considered as a channeling
agent (Mcraig, 1990; Pongjanyakul et al., 2004) by achievement
of interconnecting hydrophilic channels throughout the GMS
matrix. This result leads to enhance the penetration of dissolu-
tion medium into the matrix and to facilitate creating of more
pores inside the tablet as well as more swelling of avicel parti-
cles. This leads to increase in the wettability and to rapid solvent
penetration inside the tablets to dissolve the drug more rapidly
and to get diffused out (Dakkuri et al., 1978; El-Shanawany,
1993; Nakai et al., 1977; Bhi Said and Al-Shora, 1980).
It is concluded that the key of the preparation of plastic
matrix is dependent mainly on the controlling of the percent
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plex. The Peppas and Sahlin equation(1989) Eq. (2) can be ap-
plied irrespective of the dosage form geometry. The ﬁrst term
of the right hand side of the equation is the Fickian contribu-
tion, while the second term is the Case II relaxation contribu-
tion. The coefﬁcient m for these matrices was 0.43, according
to their aspect ratio. The K1 = 0.374 signiﬁcantly higher than
K2 = 0.056, and from the values of K1 and K2 obtained from
Eq. (2). It is possible to calculate the fraction of Fickian release
by using Eq. (3) which is 60% of total drug released suggesting
that the diffusion contribution as the major factor controlling
drug release (Lu et al., 2007).
4. Conclusion
The results showed that the evaporation method has superior
effect over kneaded method in increasing the solubility of NC
when a complexes where prepared between NC and HPbCD
for increasing the solubility of NC in alkaline medium. Also,
plastic matrix consisting of GMS and PEG4000 could control
the release of NC during 8 h to be complying with the FDA
and USP requirements for extended release tablets. In addition,
the proportion of GMS and PEG4000 plays a critical role for
obtaining a suitable plastic matrix while PEG4000 is considered
as a channeling agent for increasing the extent and rate of re-
lease of NC from the tablets. It is clear that the diffusion of
drug was the predominant mechanism of the drug kinetic re-
lease from all prepared tablets; on other hand, DSC, X-ray,
FT-IR, and microscopic examination show formation of amor-
phous solid dispersion and approximately complete trapping of
NCwithin the HPbCD cavity. NCwas prepared with GMS as a
solid dispersion system to investigate the probable effect of
GMS on NC, X-ray did not show any change in the crystalline
nature of NC, while DSC show a small shifting in the melting
point of GMS, FT-IR spectra did not indicate any change in
NC when prepared with GMS as a solid dispersion. Case I or
Fickian diffusion was the main transport mechanism of NC
from all prepared tablets by NC:GMS and NC:GMS:PEG4000
solid dispersion.
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